Literature DB >> 12031879

Expression of hexokinase II and Glut-1 in untreated human breast cancer.

Raya S Brown1, Tonya M Goodman, Kenneth R Zasadny, Joel K Greenson, Richard L Wahl.   

Abstract

Expressions of HKII and Glut-1 were studied in untreated primary human breast cancers by immunohistochemistry. 79% of the breast cancers were HKII-positive and 61% were Glut-1-positive. Average positive malignant cell areas were 66 +/- 41% for HKII and 29 +/- 36% for Glut-1. HKII staining was cytoplasmic, suggesting mitochondrial localization with no variations in staining intensities. Glut-1 staining was heterogeneous, cytoplasmic and membranous and varied with histology and tumor stage. Cells expressing HKII did not always express Glut-1 and vice versa. Increased FDG-uptake appeared to be associated with increased Glut-1 expression (P = 0.021), but not with HKII expression (p = 0.6).FDG uptake in breast cancer tissue appears to be associated with the extent of immunodetectable expression of Glut-1, but not that of HKII, and FDG uptake may differ between individual tumors depending on tumor stage and histology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12031879     DOI: 10.1016/s0969-8051(02)00288-3

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  38 in total

1.  [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.

Authors:  Marcelo Mamede; Tatsuya Higashi; Masanori Kitaichi; Koichi Ishizu; Takayoshi Ishimori; Yuji Nakamoto; Kazuhiro Yanagihara; Mio Li; Fumihiro Tanaka; Hiromi Wada; Toshiaki Manabe; Tsuneo Saga
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

2.  Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma.

Authors:  Yoshihiro Nishiyama; Yuka Yamamoto; Toshihide Monden; Yasuhiro Sasakawa; Nobuyuki Kawai; Katashi Satoh; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-29       Impact factor: 9.236

3.  Functional properties and genomics of glucose transporters.

Authors:  Feng-Qi Zhao; Aileen F Keating
Journal:  Curr Genomics       Date:  2007-04       Impact factor: 2.236

4.  Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysis.

Authors:  Maren Bretschi; Caixia Cheng; Hendrik Witt; Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Wolfhard Semmler; Tobias Bäuerle
Journal:  J Cancer Res Clin Oncol       Date:  2012-12-11       Impact factor: 4.553

5.  Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study.

Authors:  Mei Tian; Hong Zhang; Yoshiki Nakasone; Kenji Mogi; Keigo Endo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-10       Impact factor: 9.236

Review 6.  18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.

Authors:  Hossein Jadvar; Abass Alavi; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

7.  In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia.

Authors:  Craig K Abbey; Alexander D Borowsky; Erik T McGoldrick; Jeffrey P Gregg; Jeannie E Maglione; Robert D Cardiff; Simon R Cherry
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-26       Impact factor: 11.205

8.  Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines.

Authors:  Toshio Sasajima; Tadashi Miyagawa; Takamitsu Oku; Juri G Gelovani; Ronald Finn; Ronald Blasberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-13       Impact factor: 9.236

9.  [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

Authors:  Wen Wee Ma; Heather Jacene; Dongweon Song; Felip Vilardell; Wells A Messersmith; Dan Laheru; Richard Wahl; Chris Endres; Antonio Jimeno; Martin G Pomper; Manuel Hidalgo
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

10.  Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells.

Authors:  Yong Yang; Joy Wolfram; Kathryn Boom; Xiaohong Fang; Haifa Shen; Mauro Ferrari
Journal:  Cell Biochem Funct       Date:  2012-10-08       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.